Quick Facts: Therapeutic Domains

• May be utilized for the management of symptoms associated with acute nausea.
• Is often considered for the symptomatic relief of vomiting.
• May be administered for certain gastrointestinal motility issues, such as delayed stomach emptying (gastroparesis).

Vesperum is used for the symptomatic management of acute nausea and vomiting. This medication is intended to help alleviate these uncomfortable feelings in appropriate patient populations.

Additionally, it is often considered for the relief of symptoms related to specific gastrointestinal motility disorders. This includes conditions like gastroparesis, where the stomach empties food into the small intestine at a slower than typical rate. By influencing the gastrointestinal tract, Vesperum is understood to help in the transit of stomach contents.

The medication is sometimes administered in cases where nausea and vomiting are related to other treatments, such as certain cancer therapies. Its use is generally intended to provide short-term relief for these symptoms. For detailed information and restrictions regarding usage, professional medical guidance should be sought.

Regulatory References

1. EMA therapeutic overview

Eligibility Scope

Official Restrictions and Non-Eligibility

Vesperum is strictly contraindicated in numerous patient populations based on authoritative government labels. These exclusions are due to the potential for serious cardiac adverse effects or interference with the medicine's prokinetic action:

• Cardiac/Electrolyte Status: Contraindicated in patients with pre-existing QTc prolongation, significant electrolyte disturbances (hypokalemia, hypomagnesemia), or underlying cardiac conditions.
• Organ Function: Moderate to severe hepatic impairment is an absolute contraindication. Use in severe renal impairment requires a reduction in the frequency of administration.
• Comorbidities: Prohibited for patients with a prolactin-releasing pituitary tumor (prolactinoma) or any condition where stimulating gastric motility would be harmful (e.g., GI bleeding).
• Co-Administration: Vesperum is contraindicated if taken concurrently with potent CYP3A4 inhibitors or other QT-prolonging medicines.

Age and Reproductive Status

Use in children younger than 12 years or weighing less than 35 kg is generally not recommended or contraindicated in most regulated markets. Use in pregnancy is generally not recommended unless the benefit outweighs the risk due to limited data, and use during lactation is not recommended as the drug is excreted in breast milk.

Official Interaction Restrictions

The regulatory interaction profile for Vesperum is characterized by critical pharmacokinetic and pharmacodynamic interactions that necessitate mandatory restrictions. Co-administration is strictly contraindicated with strong or moderate CYP3A4 inhibitors, such as antifungals (e.g., ketoconazole) and certain macrolide antibiotics (e.g., clarithromycin). This prohibition exists because inhibition of the CYP3A4 metabolic pathway causes a significant increase in Vesperum plasma exposure, documented to rise by up to 3- to 10-fold. Co-administration is also contraindicated with any medicinal products that prolong the QTc interval, as this creates a serious, additive pharmacodynamic risk to cardiac conduction. The substance Grapefruit Juice is formally identified as a contraindicated CYP3A4 inhibitor.

Documented Pharmacokinetic Effects

Vesperum causes a documented pharmacokinetic interaction with Levodopa, leading to an increase of up to 30 to 40% in plasma Levodopa concentration. Antacids and Antisecretory drugs must not be taken simultaneously with oral Vesperum formulations, as regulatory documents require dose separation to prevent compromised absorption. Furthermore, the medicine is formally contraindicated in patients with moderate or severe hepatic impairment due to impaired drug clearance. For individuals with severe renal impairment, a reduced dosing frequency is formally required on repeated administration due to a prolonged elimination half-life, a constraint necessary to prevent drug accumulation.

Vesperum functions as a selective allosteric antagonist at the GABA-A alpha5 subunit receptor, primarily localizing its activity within the limbic system and cortical regions. The molecular interaction involves non-competitive binding to a distinct allosteric site on the receptor complex, inducing a conformational shift that reduces the binding affinity for the endogenous neurotransmitter gamma-aminobutyric acid (GABA). This inhibitory interaction results in a reduction of chloride ion influx through the receptor-associated channel pore. The consequent alpha5-mediated reduction in hyperpolarization of the postsynaptic neuron leads to a quantifiable increase in neuronal excitability within targeted circuits. This change in cellular signaling propagates through the hippocampus, modulating the long-term potentiation (LTP) molecular machinery. At the system level, this modulation translates into an altered synaptic transmission profile across specific corticolimbic pathways, affecting the global balance of excitatory and inhibitory neurotransmission.

Official Administration Guidelines

Instruction Classifications (High-Level)

Resulting Procedural Structure

Official step sequence:

• Take the 10 mg dose (tablet or suspension) before a meal.
• Wait a minimum of 8 hours before the next administration.
• Do not exceed the 30 mg maximum dose over 24 hours.

Connection to the overall use protocol: These explicit administration instructions establish a rigorous framework for Vesperum’s intake regarding quantity and timing. The protocol defines the required routes, the absolute limits on daily intake (30 mg), and the mandatory duration limit for acute use, standardizing administration.

Research evidence / Overview of studies for Vesperum

Research Evidence for Symptoms of Delayed Stomach Emptying (Gastroparesis)

Research has used highly controlled study designs, including short-term, placebo-controlled Randomized Controlled Trials (RCTs), to explore Domperidone's use in studies examining conditions characterized by functional limitations, specifically delayed stomach emptying. These studies monitored patient-reported outcomes describing perceived discomfort related to physical discomfort in the upper digestive tract. Researchers examined adults diagnosed with gastroparesis, including specific groups such as those with Diabetic and Idiopathic Gastroparesis. Outcomes measured included changes in patient-reported severity of symptoms like nausea, vomiting, bloating, and early satiety, often using standardized scales. Research also examined objective measures related to the rate of stomach emptying.

Findings describe patterns observed in these studies, which reported how symptoms evolved in the observed populations during the study period. Long-term data was collected in observational cohort studies which were used in research contexts involving fluctuating or unstable symptoms over many months. Uncertainty remains regarding outcomes beyond the initial short-term study duration. Additionally, some studies explored whether the change in patient-reported symptoms always aligns precisely with objective changes in the rate of food moving through the stomach.

Research Evidence for Acute Nausea and Vomiting

Research examining Domperidone for conditions involving periods of heightened symptoms, specifically acute nausea and vomiting, comes from short-term, placebo-controlled RCTs. These studies explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. Researchers studied adults and adolescents (aged 12 years and older) experiencing episodic or acute changes. The primary outcomes measured were the cessation of vomiting episodes and changes in the intensity of nausea symptoms, typically assessed over a very limited time interval, such as 48 hours to one week.

Evidence in Specific Patient Groups

Domperidone was evaluated in adults and adolescents for both motility and acute symptom relief. Dedicated research was also conducted to examine its use in younger pediatric patients (children younger than 12 years). However, the findings for the pediatric group were mixed, and subsequent regulatory reviews have described patterns related to a situation where data were not sufficient to establish findings in this specific age group.

Evidence Gaps and Areas of Uncertainty

The research highlights several areas where certainty remains low. One major limitation frame is that long-term effects are not fully established by rigorous trials, particularly for managing motility conditions. The durability or persistence of any observed changes after study completion is not fully established by the existing evidence. Furthermore, comparative research is limited regarding how the compound was studied in comparison to other anti-emetic or prokinetic therapies in head-to-head trials. Research provides context but not individual predictions, and studies help show what has been observed so far.

Key Studies & References

1. A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis

Common questions about Vesperum (FAQ)

Q: Is Vesperum a painkiller or an anti-inflammatory drug?

According to the official product information, Vesperum (Domperidone) is classified as a Peripheral Dopamine Antagonist and an Anti-emetic/Prokinetic Agent. This means its primary function is to help with nausea, vomiting, and stomach movement. It is not classified as a painkiller or an anti-inflammatory drug.

Q: Are there any long-term studies on the safety of Vesperum?

Official guidance indicates that Vesperum is authorized for short-term use only, which typically means treatment should not exceed one week. This restriction is based on regulatory reviews which recognized an increased risk of serious cardiac side effects, such as heart rhythm issues, associated with higher doses and longer durations of use. Studies focusing on long-term safety have not fully established these effects.

Q: Is Vesperum ever used for conditions other than its main approved use?

Vesperum is officially authorized only for the relief of symptoms related to nausea and vomiting and certain symptoms associated with delayed stomach emptying. The official label does not provide information or authorization for its use in treating other health conditions.

Q: Can Vesperum affect my ability to drive or operate machinery?

Regulatory information suggests that Vesperum has a no or negligible influence on the ability to drive or use machines. However, uncommon side effects such as drowsiness and dizziness have been reported. If these effects occur, activities requiring full alertness, like driving or operating machinery, may need to be approached with caution.

Q: Can teenagers or children take Vesperum?

Vesperum is authorized for use in adolescents aged 12 years and older who weigh 35 kg or more, for short-term use. Official guidance indicates that use in children younger than 12 years or those weighing less than 35 kg is generally not recommended, as official documentation indicates that the data were not sufficient to establish a positive benefit-risk profile in these younger groups.

Q: What is the difference between Vesperum tablets and Vesperum capsules?

The official documentation indicates that Vesperum is primarily available as film-coated tablets and an oral suspension (liquid). Differences exist between these authorized forms regarding their exact strength and specific non-active ingredients, but official product information typically does not list an authorized capsule formulation.

Q: Has Vesperum been approved by major health regulatory bodies?

Yes, Vesperum (Domperidone) is authorized and regulated by major international bodies, including the European Medicines Agency (EMA) and various national health authorities. Its use is subject to the specific prescribing and safety information published by these regulatory bodies.

Q: Are there any less common, but reported, side effects of Vesperum?

Yes, official regulatory documents list side effects that are less common. These include Uncommon effects (which may affect up to 1 in 100 people), such as anxiety and diarrhea. There are also reactions listed with a Frequency Not Known from post-marketing reports, which include seizures and severe allergic reactions.

Q: What should I do if I accidentally take more than the recommended amount of Vesperum?

Regulatory guidance advises that individuals should seek medical advice immediately following the intake of more than the recommended amount. Overdose may potentially lead to symptoms such as agitation, changes in consciousness, uncontrolled movements, or disorientation.

Q: Do any common conditions (like diabetes or asthma) affect how Vesperum works?

Official warnings state that Vesperum is contraindicated (should not be used) in patients with significant underlying cardiac diseases or those with moderate to severe hepatic impairment (liver problems). It is also prohibited if there is a risk of gastrointestinal bleeding or obstruction.

Q: Is Vesperum known to cause weight gain or loss?

Weight gain or weight loss is not officially listed as a common or uncommon side effect in the regulatory product information. Therefore, these effects are not formally recognized as being caused by the medicine.

Q: Can Vesperum be split in half?

Regulatory instructions typically specify that tablets should be swallowed whole. Unless the tablet is specifically scored (marked for splitting) and you have been advised to split it by a healthcare professional, it is typically recommended not to divide it.

Q: Can Vesperum interfere with sleep patterns?

The official product information lists drowsiness as an uncommon side effect. While general drowsiness is noted, specific interference with the complexity of sleep patterns (such as insomnia or nightmares) is not explicitly detailed in the side effect profile.

Q: Are there specific times of day Vesperum is best taken?

The official instructions emphasize taking Vesperum before meals (typically 15 to 30 minutes prior) because food can delay its absorption. There is no official preference for taking it in the morning or at night, as long as a minimum 8-hour interval is maintained between doses.

How to Store and Dispose of Vesperum

All storage and disposal instructions for Vesperum (Domperidone) are based on official regulatory documentation and must be followed to maintain product integrity and safety.

These official requirements ensure the medicine remains stable until its expiration and define the environmental rules for pharmaceutical waste handling, prohibiting disposal through public water systems.